newsfilter
← Latest News
Business Wire·

bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board

BIAFBIAFW
  • bioAffinity Technologies, Inc. appointed David Ost, MD, MPH; Daniel Sterman, MD; and J. Scott Ferguson, MD to its Medical & Scientific Advisory Board.
  • The new appointments support the Company's strategic priority to integrate its noninvasive CyPath® Lung diagnostic test into the standard of care for indeterminate pulmonary nodules.
  • The expanded advisory panel now includes current members David Hill, MD; Neil Alexis, PhD; Sheila Habib, MD; Audie L. Murphy Memorial Veterans Hospital's Sandeep Bansal, MD.
  • Chief Medical Officer Gordon Downie, MD, PhD stated the board's experience aids the mission to detect lung cancer at early, treatable stages.
  • President & CEO Maria Zannes noted the new members will guide clinical implementation & broader adoption of the CyPath® Lung platform.
  • CyPath® Lung utilizes flow cytometry & proprietary AI to identify malignancy markers in patient sputum using a fluorescent porphyrin.
  • Clinical study results demonstrated 92% sensitivity, 87% specificity, & 88% accuracy for detecting lung cancer in high-risk patients with nodules under 20 millimeters.
  • The test is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a bioAffinity subsidiary.
  • The press release includes standard forward-looking statements regarding future expectations & risks associated with the Company's operations.